• Lisata Therapeutics began a corporate reorganization on Aug. 3, 2026, cutting its workforce by about 72% effective immediately.
• Move targets lower operating expenses as the company pursues strategic options.
• Restructuring costs expected at about $1.2 million, mainly severance and termination benefits, incurred through the quarter ending Sept. 30, 2026.
• Executive Vice President of R&D and Chief Medical Officer Kristen K. Buck was terminated; contract provides 12 months base salary and target bonus, COBRA up to 12 months.
• Board authorized a $200,000 cash retention bonus for Chief Accounting Officer James Nisco, payable within 30 days of Dec. 31, 2026 subject to continued employment.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lisata Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001140361-26-031028), on August 04, 2026, and is solely responsible for the information contained therein.